Scalper1 News
Big biotech United Therapeutics (UTHR) agreed to sell its priority-review voucher to AbbVie (ABBV) for $350 million, giving United an infusion of cash and AbbVie a chance to speed up the FDA approval of one of its drugs. United gained the Rare Pediatric Disease Priority Review Voucher (PPRV) upon the March 10 approval of Unituxin, a treatment for a rare childhood cancer called neuroblastoma. The FDA started the PPRV program to encourage the Scalper1 News
Scalper1 News